Francisco Socola Cuzco, MD
Hematology & Oncology · Sacramento, CANPI 1508153339
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.5%. 2025 is the largest year on record at $9,929, more than ten times the $599 reported in 2019.
Across 77 payments — averaging $302.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- Agios Pharmaceuticals, Inc.$4K
- Incyte Corporation$3K
- Geron Corporation$3K
- Blueprint Medicines Corporation$3K
- Invivyd Inc$2K
- plus $4K from 24 others
Across 35 payments — averaging $8227.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$167K
- Takeda Pharmaceuticals U.S.A., Inc.$69K
- Gilead$40K
- Macrogenics, Inc.$9K
- AbbVie$2K
What the payments were for
- Consulting fees$10,08343%
- Speaking & faculty fees$11,00947%
- Travel & lodging$1541%
- Food & beverage$1,5987%
- Education$4682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $4,545 |
| Agios Pharmaceuticals, Inc. | 3 | $3,930 |
| Incyte Corporation | 9 | $3,486 |
| Geron Corporation | 3 | $2,714 |
| Blueprint Medicines Corporation | 1 | $2,599 |
| Invivyd Inc | 1 | $2,223 |
| Pfizer | 3 | $1,527 |
| Daiichi Sankyo Inc. | 2 | $666 |
| Astellas Pharma US Inc | 7 | $345 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $176 |
| AstraZeneca(2 entities) | 2 | $161 |
| Seagen Inc. | 3 | $151 |
| AbbVie | 2 | $138 |
| Bristol Myers Squibb | 7 | $120 |
| BTG International Inc. | 1 | $98 |
| Jazz Pharmaceuticals Inc. | 1 | $78 |
| Novartis | 3 | $63 |
| Adaptive Biotechnologies Corporation | 2 | $45 |
| Beigene USA, Inc. | 2 | $35 |
| Genmab U.S., Inc. | 1 | $30 |
| Karyopharm Therapeutics Inc. | 2 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| EUSA Pharma (US) LLC | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Gilead | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Servier Pharmaceuticals LLC | 1 | $14 |
| Dendreon Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,311 in reported general payments places this provider in the 80th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Sacramento
- Nitin RohatgiSacramento$814K
- Mehrdad AbediSacramento$613K
- Adam GiermaszSacramento$438K
- Scott ChristensenSacramento$349K
- David GandaraSacramento$336K
- Joseph TuscanoSacramento$258K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.